Mostrando 8 resultados de: 8
Filtros aplicados
Publisher
Bionatura(1)
Cancer Biology and Therapy(1)
Cancer Biotherapy and Radiopharmaceuticals(1)
Clinical and Translational Immunology(1)
Immunotherapy(1)
Objetivos de Desarrollo Sostenible
ODS 10: Reducción de las desigualdades(8)
ODS 3: Salud y bienestar(8)
ODS 17: Alianzas para lograr los objetivos(7)
ODS 9: Industria, innovación e infraestructura(1)
Origen
scopus(8)
An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: Report of three cases
ArticleAbstract: In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the diPalabras claves:CD6 molecule, coronavirus 2, covid-19, cytokine-release syndrome, IL-6, Itolizumab, Monoclonal antibody, SARS-COV-2Autores:Añe-Kouri A.L., Berrio J., Caballero A., Caballero J.A., Cepeda M., Cervantes J.B., Figueredo C., Filgueira L.M., Herrera C., Leon K., Lorenzo G., Lovelle O.A., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania CrombetFuentes:scopusEvaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials
ArticleAbstract: Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: hPalabras claves:Epidermal growth factor receptor, Head and neck tumors, Humanized monoclonal antibody, nimotuzumabAutores:Aliuska Frías, Carmen Elena Viada, García L., Mabel Álvarez, Macías A.E., Mestre B.F., Osorio M., Pérez Ruiz L., Ramos M., Robaina M., Santiesteban Y., Tania Crombet, Vega A.M.Fuentes:scopusPhase I clinical evaluation of a neutralizing monoclonal antibody against Epidermal Growth Factor Receptor
ArticleAbstract: Ior egf/r3 a neutralizing monoclonal antibody (mAb) against Epidermal Growth Factor Receptor (EGFR)Palabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, Phase I clinical trial, Tyrosine kinase inhibitorsAutores:Catalaá M., Fernández E., Iznaga N., Neninger Vinageras E., Peérez R., Ramos M., Rodríguez N., Tania Crombet, Torres O.Fuentes:scopusPhase i/ii clinical trial of the humanized anti-egf-r monoclonal antibody h-r3 labelled with <sup>99m</sup>tc in patients with tumour of epithelial origin
ArticleAbstract: To evaluate the biodistribution, internal radiation dosimetry and toxicity of the humanized MAb h-R3Palabras claves:biodistribution, Dosimetry, Humanized MAb, RadioimmunodiagnosisAutores:Aguilar V., Batista J.F., Coca M.A., Hernández A., Iznaga-Escobar N., Neninger Vinageras E., Perera A., Pérez M., Ramos M., Romero S., Sánchez E., Tania Crombet, Torres L.Fuentes:scopusNimotuzumab: beyond the EGFR signaling cascade inhibition
ReviewAbstract: One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activatesPalabras claves:antibody-dependent cell mediated cytotoxicity (ADCC), eGFR, HLA class I molecules, monoclonal antibodies, Natural killer cells, T cellsAutores:Chao L., Iznaga N., Lavastida A., Mazorra Z., Ramos M., Sanchez B., Tania CrombetFuentes:scopusSystemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab
ArticleAbstract: Nimotuzumab (h-R3) is a humanized anti-epidermal growth factor receptor monoclonal antibody (mAb) rePalabras claves:animal model, CETUXIMAB, Epidermal growth factor receptor, General toxicity, H-R3, Monkeys, nimotuzumab, Skin toxicityAutores:Arteaga M.E., Ballester-Labrada A., Baro F., Boleda M., Casacó Parada A.R., Charro L., Fuentes D., García M., González B., González C., Hernández O., Ledón N., Macías A.E., Morales Y., Orphee R., Pardo B., Pérez A., Ramos M., Rodríguez V., Rodriquez L., Subirós N., Tania Crombet, Viña L.Fuentes:scopusTreatment of COVID-19 patients with the anti-CD6 antibody itolizumab
ArticleAbstract: Objectives: COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on maturPalabras claves:CD6, covid-19, Cytokine release syndrome, Itolizumab, Monoclonal antibody, SARS-COV2Autores:Arencibia M., Betancourt J., Caballero A., Cabrera L., Castillo U., Cepeda M., Despaigne R.E., Diaz H., Domecq M., Escalona A., Estevez D., Filgueira L.M., García Y., Hidalgo C.J., Leon K., Lorenzo G., Lorenzo P., Martinez A., Mazorra Z., Meriño E., Ortega L.M., Ramírez A., Ramos M., Saavedra Hernández D., Sánchez L., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.Fuentes:scopusUse of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
ArticleAbstract: Purpose: To evaluate safety and preliminary efficacy of the humanized anti-epidermal growth factor rPalabras claves:Autores:Alvarez D., Cruz T., Del Castillo R., Fernández E., Figueredo R., Iznaga-Escobar N., Koropatnick J., Lage Davila A., Leonard I., Mon R., Osorio M., Pérez R., Ramos M., Renginfo E., Roca C., Tania Crombet, Torres O.Fuentes:scopus